Navigation Links
Tengion Appoints Jeff Randall to Board of Directors
Date:2/27/2008

EAST NORRITON, Pa., Feb. 27 /PRNewswire/ -- Tengion Inc., a clinical stage regenerative medicine company focused on the development of neo-organs and neo-vessels, announced today that it has appointed Jeff Randall to its Board of Directors. Mr. Randall brings more than 25 years experience as a senior- level executive, CFO and CEO at public and private companies to Tengion, including expertise in the healthcare, device manufacturing and electronics industries.

"We are pleased to welcome Jeff to the Tengion Board of Directors," said Steven Nichtberger, M.D., President and Chief Executive Officer of Tengion. "His expertise in developing the financial infrastructure for biotech companies will be a valuable addition to our Board and we look forward to working with him."

Mr. Randall's career has included serving as CFO at seven companies, three of which then appointed him to the post of CEO. Now a financial consultant, he most previously held management team positions at Eximias Pharmaceutical Corporation and i-STAT Corporation and has extensive experience working with and serving on Boards of Directors. Mr. Randall received his B.S. from The Pennsylvania State University, his M.B.A. from Northeastern University and served in the U.S. Air Force.

"Tengion's technology and the strength of its management team and Board of Directors made this an exciting opportunity," said Mr. Randall. "I am looking forward to working with the company and my fellow members of the Board to realize Tengion's potential and help the company achieve its corporate goals."

About Tengion

Tengion, a clinical stage biotechnology company, has pioneered the Autologous Organ Regeneration Platform(TM) that catalyzes the body's innate ability to regenerate. Tengion's neo-organs and neo-tissues in development, such as bladders and vessels, combine biocompatible materials and a patient's own (autologous) cells to regenerate diseased and failing organs and tissues. Tengion's product candidates have the potential to cure - rather than treat - organ and tissue failure, enabling people to lead healthier lives without donor transplants or the side effects of related therapies. For more information on the company and current clinical trials, visit Tengion online at: http://www.tengion.com.


'/>"/>
SOURCE Tengion Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Preclinical Efficacy Data Demonstrate Ability of Tengions Neo-Bladder Augment to Restore Bladder Function
2. Tengion to Present at Merrill Lynch Global Pharmaceutical, Biotechnology & Medical Device Conference
3. BioVex Appoints Dr. Thaddeus Pullano as VP, Quality Assurance
4. Codexis Appoints Singapore Laboratories Managing Director
5. Emisphere Technologies, Inc. Appoints Paul Lubetkin as Vice President and General Counsel
6. Nektar Therapeutics Appoints Tim Harkness as Chief Financial Officer
7. Anadys Pharmaceuticals Appoints Steve Worland, Ph.D. as President and Chief Executive Officer
8. NanoLogix Inc. Appoints Director of IP and Makes Progress on Rapid Anthrax Detection
9. Emisphere Technologies, Inc. Appoints Michael R. Garone chief financial officer
10. Nektar Therapeutics Appoints Lutz Lingnau as New Board Member
11. NeurogesX Appoints New Director to the Board
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/11/2017)... , May 11, 2017   BioLife Solutions , Inc. ... marketer of proprietary clinical grade cell and tissue hypothermic ... the "Company"), today reported operational highlights and financial results for ... media product sales reached a new high of $2.4 million ... over the same period in 2016. Revenue growth was driven ...
(Date:5/11/2017)... Linda, Ca (PRWEB) , ... May 11, 2017 ... ... and primary rodent neurons both are excellent resources for disease modeling and drug ... and further differentiated into mature neurons for various applications, however, these often contain ...
(Date:5/10/2017)... ... May 10, 2017 , ... Shimadzu Scientific Instruments (SSI) ... host of technologically advanced features, resulting in a modernized instrument that improves user ... a higher return on investment. , Engineered with the analyst in mind, ...
(Date:5/10/2017)... ... May 10, 2017 , ... ... Center as VP Corporate Development. Cervantes brings over 20 years’ experience in ... and academic research environments. , In this newly created position at the ...
Breaking Biology Technology:
(Date:3/30/2017)... YORK , March 30, 2017 Trends, ... type (physiological and behavioral), by technology (fingerprint, AFIS, iris ... voice recognition, and others), by end use industry (government ... and immigration, financial and banking, and others), and by ... Europe , Asia Pacific , ...
(Date:3/27/2017)... ROCKVILLE CENTRE, N.Y. , March 27, 2017 ... by Healthcare Information and Management Systems Society (HIMSS) ... Analytics Outpatient EMR Adoption Model sm . In ... top 12% of U.S. hospitals using an electronic ... recognized CHS for its high level of EMR ...
(Date:3/23/2017)... 23, 2017 The report "Gesture Recognition and Touchless Sensing ... Geography - Global Forecast to 2022", published by MarketsandMarkets, the market is expected ... 29.63% between 2017 and 2022. Continue Reading ... ... ...
Breaking Biology News(10 mins):